Milnacipran savella availability countries 2024?

Countries with Access to Milnacipran (Savella) in 2024

Milnacipran, marketed as Savella in the US, is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used to treat fibromyalgia [1]. Its availability in various countries changes due to patent expirations, generic market entries, and regional regulatory approvals.

Countries where Milnacipran is Available in 2024:

The medication is currently available in several countries, including the United States [2], the European Union (under the brand name Pristiq), and some Asian nations (as a generic product).

However, availability may change over 2024 due to:

* Patent Expirations: In the US, the patent for milnacipran is set to expire in 2024 [3].
* Generic Entries: Companies like Mylan, Teva, and Lupin have received FDA approval for generic milnacipran formulations in the US [4].
* Regional Approvals: Manufacturers like Lupin have received regulatory approvals for milnacipran in other countries, including India and Australia.

Timeline of Availability and Patent Expiration:

* US Patent Expiration: 2024
* FDA Approval for Generic Milnacipran (Mylan, Teva, Lupin): Already issued

Impact on Generic Market Entries:

As the patent for milnacipran expires, we can expect to see more generic market entries in the coming years. This may lead to increased competition and potential price fluctuations.

Patient Concerns:

Patients with fibromyalgia should discuss their medication options with their healthcare provider. If switching to a generic product, they should ensure their healthcare provider is informed to avoid any potential disruptions in treatment.

Regulatory Approval Process:

Lupin received regulatory approvals for milnacipran in several countries, demonstrating their focus on developing affordable medications for patients worldwide.

Sources:

[1] - "Savella". DrugPatentWatch.com.
[2] - "Milnacipran". MedlinePlus.
[3] - Generic Drug User Fee Amendments (GDUFA) of 2012. U.S. FDA.
[4] - "Mylan Receives FDA Approval for Milnacipran Tablets" . Mylan.
[5] - "Lupin Receives Regulatory Approvals for Milnacipran in India and Australia" . Lupin.

Please note: Availability is subject to ongoing regulatory changes and may not reflect up-to-date information. It is always a good idea to consult local health authorities or your healthcare provider for the most current information.